[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357260-105":59,"doc-detail-357260-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-and-clinical-significance-of-germline-pathogenic-variants-identified-by-multigene-panel-testing-in-high-risk-japanese-patients-with-breast-cancer","Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer","","Background: In Japan, BRCA genetic testing for hereditary breast and ovarian cancer is covered by medical insurance, while other breast cancer susceptibility genes are seldom examined due to coverage limitations. Methods: A multigene panel testing (MGPT) approach was applied to breast cancer patients meeting BRCA testing clinical criteria. Results: Among 494 patients, 45 germline pathogenic variants were found (9.11%), with higher detection tied to specific clinical criteria. Conclusions: MGPT identifies pathogenic variants beyond BRCA1/2, supporting clinical management for patients and relatives.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-clinical-significance-of-germline-pathogenic-variants-identified-by-multigene-panel-testing-in-high-risk-japanese-patients-with-breast-cancer/357260/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-clinical-significance-of-germline-pathogenic-variants-identified-by-multigene-panel-testing-in-high-risk-japanese-patients-with-breast-cancer/357260.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study aim regarding genetic testing in high-risk Japanese breast cancer patients?","Question",{"text":112,"@type":113},"To assess the prevalence and clinical relevance of germline pathogenic variants using multigene panel testing in patients who met BRCA genetic testing criteria under insurance coverage.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients and germline pathogenic variants were identified?",{"text":117,"@type":113},"Among 494 patients, 45 germline pathogenic variants were identified, corresponding to 9.11%.",{"name":119,"@type":110,"acceptedAnswer":120},"Which BRCA genetic testing criteria showed higher GPV detection rates?",{"text":121,"@type":113},"Criteria associated with GPV detection rates greater than 10% included diagnosis at age ≤45, triple-negative breast cancer at age ≤60, and having at least one close blood relative within the third degree on the same side with breast, ovarian, or pancreatic cancer.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357260,1790156750,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":143,"preview_page_count":19,"preview_urls":144},4398046744996,"Breast Cancer (2026) 33:887–895  \n[https://doi.org/10.1007/s12282-026-01863-2](https://doi.org/10.1007/s12282-026-01863-2)  \nORIGINAL ARTICLE  \nPrevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer  \nMiharu Kano1 · KanaeTaruno1 · Mayuko Inuzuka1 · Reiko Makino1 · Mieko Takeuchi1 · Misato Suzuki2 · Kumiko Kida3 · JunkoTakei3 · Aiko Nagayama4 · Tetsu Hayashida4 · Yurie Haruyama5 · Takayuki Ueno5 · Chie Watanabe1 · Yasuyuki Kojima1 · Rumi Sasai6 · Mikiko Endo6 · Yukihide Momozawa6 · Seigo Nakamura1  \nReceived: 20 January 2026 / Accepted: 4 May 2026 / Published online: 13 May 2026 © The Author(s) 2026  \nAbstract  \nBackground In Japan, BRCA genetic testing for the diagnosis of hereditary breast and ovarian cancer is covered by medical insurance. However, other breast cancer (BC) susceptibility genes are rarely examined in these patients, primarily because medical insurance does not cover testing for these genes.  \nMethods A multigene panel testing (MGPT) was conducted on patients with BC who met the clinical criteria for BRCA genetic testing.  \nResults Of the 494 patients, 45 germline pathogenic variants (GPVs) were identified (9.11%). The BRCA genetic testing criteria items with GPV detection rates > 10% were as follows: “diagnosed at age ≤ 45 years,”“diagnosed with triple-negative breast cancer (TNBC) at age ≤ 60 years” and “≥1 close blood relative within the third degree on the same side of the family with breast, ovarian, or pancreas cancer.”  \nConclusions . MGPT can identify GPVs in genetically high-risk BC patients, including both BRCA1/2 and non-BRCA genes. Thus, MGPT may be an effective approach to support appropriate clinical management for both patients and their relatives.  \nKeywords Genetic testing · Breast cancer · Hereditary breast and ovarian cancer · Japan  \nSeigo Nakamura Deceased. Contribution completed prior to death.  \n􀀍 Kanae Taruno[ktaruno@med.showa-u.ac.jp](ktaruno@med.showa-u.ac.jp)  \n1 Division of Breast Surgery, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan  \n2 Center for Medical Genetics, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan  \n3 Department of Breast Surgical Oncology, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan  \n4 Department of Breast Surgery, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan  \n5 Breast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan  \n6 Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 1-7-22 Suehiro-cho, Tsurumiku, Yokohama City, Kanagawa 230-0045, Japan  \nIntroduction  \nBreast cancer (BC) is the most commonly diagnosed cancer in women [1] . Several factors such as reproductive history, obesity, and hormonal replacement therapy contribute to BC development [2] . Germline pathogenic variants (GPVs) were also identified as a significant factor of BC [3]. According to the use of multigene cancer susceptibility panels, approximately 5%–10% of women with BC carry GPVs [4–7] . Among these, BRCA1 and BRCA2 are wellknown genes [8] . In Japan, BRCA genetic testing for the diagnosis of hereditary breast and ovarian cancer (HBOC) has been covered by medical insurance since April 2020 [9] . Although patients who fit the BRCA genetic testing criteria are considered genetically at high-risk, the detection rate of GPVs with BRCA1/2 is approximately 13%[9] . In addition, genetic testing using multigene panel testing (MGPT) is not commonly performed in Japan because it is not covered by medical insurance, resulting in the limited assessment of  \nGPVs in other genes. However, genetic analysis is important in making decisions about therapy and cancer prevention, and ","cbCaiflepx8MwoQj","https://ap.wps.com/l/cbCaiflepx8MwoQj","pdf",864980,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Risk factors and genetic background\n## Insurance coverage for BRCA testing in Japan\n## Rationale for MGPT in this population\n# Methods\n## Study design\n## Insurance coverage criteria","[{\"question\":\"What was the study aim regarding genetic testing in high-risk Japanese breast cancer patients?\",\"answer\":\"To assess the prevalence and clinical relevance of germline pathogenic variants using multigene panel testing in patients who met BRCA genetic testing criteria under insurance coverage.\"},{\"question\":\"How many patients and germline pathogenic variants were identified?\",\"answer\":\"Among 494 patients, 45 germline pathogenic variants were identified, corresponding to 9.11%.\"},{\"question\":\"Which BRCA genetic testing criteria showed higher GPV detection rates?\",\"answer\":\"Criteria associated with GPV detection rates greater than 10% included diagnosis at age ≤45, triple-negative breast cancer at age ≤60, and having at least one close blood relative within the third degree on the same side with breast, ovarian, or pancreatic cancer.\"}]","Prevalence and clinical significance of germline pathogenic variants identified by multigene panel testing in high-risk Japanese patients with breast cancer | PDF",1790129501,23,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b1c7f468b38c32b216b8ed2de52a78f.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6b9619646923bed5fffe09f10c4b79d4.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/758a084ff096ae8770a08520ff7ef6bb.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55596235f28b20beee3aa21e6faa6913.webp",980,1301]